MLAB has 36-month beta value of 0.84. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy”, 0 as “overweight”, 1 as “hold”, and 1 as “sell”.
The public float for MLAB is 5.30M, and currently, short sellers hold a 3.48% ratio of that float. The average trading volume of MLAB on July 04, 2025 was 103.76K shares.
MLAB stock’s latest price update
Mesa Laboratories, Inc (NASDAQ: MLAB) has seen a rise in its stock price by 2.75% in relation to its previous close of $100.63. However, the company has experienced a 7.31% gain in its stock price over the last five trading sessions. globenewswire.com reported 2025-07-03 that LAKEWOOD, Colo., July 03, 2025 (GLOBE NEWSWIRE) — Mesa Laboratories, Inc. (NASDAQ:MLAB) (we, us, our, “Mesa” or the “Company”) today announced that its Board of Directors has declared a regular quarterly dividend of $0.16 per share of common stock. The dividend will be payable on September 15, 2025, to shareholders of record at the close of business on August 29, 2025.
MLAB’s Market Performance
Mesa Laboratories, Inc (MLAB) has seen a 7.31% rise in stock performance for the week, with a 3.28% gain in the past month and a -14.33% plunge in the past quarter. The volatility ratio for the week is 5.17%, and the volatility levels for the past 30 days are at 4.51% for MLAB. The simple moving average for the last 20 days is 4.68% for MLAB stock, with a simple moving average of -15.71% for the last 200 days.
Analysts’ Opinion of MLAB
Many brokerage firms have already submitted their reports for MLAB stocks, with Wells Fargo repeating the rating for MLAB by listing it as a “Underweight”. The predicted price for MLAB in the upcoming period, according to Wells Fargo is $120 based on the research report published on August 28, 2024 of the previous year 2024.
Evercore ISI, on the other hand, stated in their research note that they expect to see MLAB reach a price target of $125, previously predicting the price at $100. The rating they have provided for MLAB stocks is “Outperform” according to the report published on January 04th, 2024.
KeyBanc Capital Markets gave a rating of “Sector Weight” to MLAB, setting the target price at $287 in the report published on November 10th of the previous year.
MLAB Trading at -4.60% from the 50-Day Moving Average
After a stumble in the market that brought MLAB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -33.34% of loss for the given period.
Volatility was left at 4.51%, however, over the last 30 days, the volatility rate increased by 5.17%, as shares surge +2.45% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -8.53% lower at present.
During the last 5 trading sessions, MLAB rose by +7.31%, which changed the moving average for the period of 200-days by -17.75% in comparison to the 20-day moving average, which settled at $98.78. In addition, Mesa Laboratories, Inc saw 16.90% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at MLAB starting from Owens Gary M, who sold 1,939 shares at the price of $97.12 back on Jun 16 ’25. After this action, Owens Gary M now owns 45,824 shares of Mesa Laboratories, Inc, valued at $188,312 using the latest closing price.
Archbold Brian David, the SVP Operations of Mesa Laboratories, Inc, sale 472 shares at $97.12 during a trade that took place back on Jun 16 ’25, which means that Archbold Brian David is holding 558 shares at $45,840 based on the most recent closing price.
Stock Fundamentals for MLAB
Current profitability levels for the company are sitting at:
- 0.07% for the present operating margin
- 0.61% for the gross margin
The net margin for Mesa Laboratories, Inc stands at -0.01%. The total capital return value is set at 0.06%. Equity return is now at value -1.29%, with -0.45% for asset returns.
Based on Mesa Laboratories, Inc (MLAB), the company’s capital structure generated 0.53 points at debt to capital in total, while cash flow to debt ratio is standing at 0.26. The debt to equity ratio resting at 1.14. The interest coverage ratio of the stock is 1.46.
Currently, EBITDA for the company is 42.35 million with net debt to EBITDA at 3.73. When we switch over and look at the enterprise to sales, we see a ratio of 2.98. The receivables turnover for the company is 5.74for trailing twelve months and the total asset turnover is 0.56. The liquidity ratio also appears to be rather interesting for investors as it stands at 0.63.
Conclusion
To put it simply, Mesa Laboratories, Inc (MLAB) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
